Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer

Rachel Woodford, Yanni Loh, Joanna Lee, Wendy Cooper, Ian Marschner, Craig R. Lewis, Michael Millward, Sally Lord, Richard J. Gralla, James C-H Yang, Tony Mok, Chee K. Lee

Research output: Contribution to journalReview article

Abstract

We investigate if PD-L1 expression and other clinical characteristics predict chemoimmunotherapy (CIT) benefits versus chemotherapy in advanced non-small-cell lung cancer. We performed a meta-analysis of randomized controlled trials of CIT versus chemotherapy identified through electronic searches. In seven randomized controlled trials (n =4170), CIT prolonged progression-free survival over chemotherapy (hazard ratio [HR]: 0.62; 95% CI: 0.58-0.67; p <0.00001). The treatment benefits differed between PD-L1-high (HR: 0.41; 95% CI: 0.34-0.49) and PD-L1 low (HR: 0.63; 95% CI: 0.55-0.72; interaction-p = 0.00002) and PD-L1-high and PD-L1-negative (HR: 0.72; 95% CI: 0.65-0.80; interaction-p <0.00001). Similar benefits were observed regardless of gender, EGFR/ALK status and histological subtype. PD-L1 status is predictive of CIT benefit and may assist patient selection and design of future trials.

Original languageEnglish
Pages (from-to)2371-2383
Number of pages13
JournalFuture Oncology
Volume15
Issue number20
DOIs
Publication statusPublished - Jul 2019

Cite this

Woodford, R., Loh, Y., Lee, J., Cooper, W., Marschner, I., Lewis, C. R., ... Lee, C. K. (2019). Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer. Future Oncology, 15(20), 2371-2383. https://doi.org/10.2217/fon-2019-0105
Woodford, Rachel ; Loh, Yanni ; Lee, Joanna ; Cooper, Wendy ; Marschner, Ian ; Lewis, Craig R. ; Millward, Michael ; Lord, Sally ; Gralla, Richard J. ; Yang, James C-H ; Mok, Tony ; Lee, Chee K. / Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer. In: Future Oncology. 2019 ; Vol. 15, No. 20. pp. 2371-2383.
@article{9a03001fc1604c74b13fea3195a24b0d,
title = "Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer",
abstract = "We investigate if PD-L1 expression and other clinical characteristics predict chemoimmunotherapy (CIT) benefits versus chemotherapy in advanced non-small-cell lung cancer. We performed a meta-analysis of randomized controlled trials of CIT versus chemotherapy identified through electronic searches. In seven randomized controlled trials (n =4170), CIT prolonged progression-free survival over chemotherapy (hazard ratio [HR]: 0.62; 95{\%} CI: 0.58-0.67; p <0.00001). The treatment benefits differed between PD-L1-high (HR: 0.41; 95{\%} CI: 0.34-0.49) and PD-L1 low (HR: 0.63; 95{\%} CI: 0.55-0.72; interaction-p = 0.00002) and PD-L1-high and PD-L1-negative (HR: 0.72; 95{\%} CI: 0.65-0.80; interaction-p <0.00001). Similar benefits were observed regardless of gender, EGFR/ALK status and histological subtype. PD-L1 status is predictive of CIT benefit and may assist patient selection and design of future trials.",
keywords = "chemoimmunotherapy, meta-analysis, non-small-cell lung cancer, PD-L1 expression, progression-free survival, AMERICAN SOCIETY, SQUAMOUS-CELL, OPEN-LABEL, NIVOLUMAB, CHEMOTHERAPY, DOCETAXEL, IMMUNOHISTOCHEMISTRY, PEMBROLIZUMAB, MECHANISMS, PHASE-1",
author = "Rachel Woodford and Yanni Loh and Joanna Lee and Wendy Cooper and Ian Marschner and Lewis, {Craig R.} and Michael Millward and Sally Lord and Gralla, {Richard J.} and Yang, {James C-H} and Tony Mok and Lee, {Chee K.}",
year = "2019",
month = "7",
doi = "10.2217/fon-2019-0105",
language = "English",
volume = "15",
pages = "2371--2383",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd",
number = "20",

}

Woodford, R, Loh, Y, Lee, J, Cooper, W, Marschner, I, Lewis, CR, Millward, M, Lord, S, Gralla, RJ, Yang, JC-H, Mok, T & Lee, CK 2019, 'Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer' Future Oncology, vol. 15, no. 20, pp. 2371-2383. https://doi.org/10.2217/fon-2019-0105

Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer. / Woodford, Rachel; Loh, Yanni; Lee, Joanna; Cooper, Wendy; Marschner, Ian; Lewis, Craig R.; Millward, Michael; Lord, Sally; Gralla, Richard J.; Yang, James C-H; Mok, Tony; Lee, Chee K.

In: Future Oncology, Vol. 15, No. 20, 07.2019, p. 2371-2383.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer

AU - Woodford, Rachel

AU - Loh, Yanni

AU - Lee, Joanna

AU - Cooper, Wendy

AU - Marschner, Ian

AU - Lewis, Craig R.

AU - Millward, Michael

AU - Lord, Sally

AU - Gralla, Richard J.

AU - Yang, James C-H

AU - Mok, Tony

AU - Lee, Chee K.

PY - 2019/7

Y1 - 2019/7

N2 - We investigate if PD-L1 expression and other clinical characteristics predict chemoimmunotherapy (CIT) benefits versus chemotherapy in advanced non-small-cell lung cancer. We performed a meta-analysis of randomized controlled trials of CIT versus chemotherapy identified through electronic searches. In seven randomized controlled trials (n =4170), CIT prolonged progression-free survival over chemotherapy (hazard ratio [HR]: 0.62; 95% CI: 0.58-0.67; p <0.00001). The treatment benefits differed between PD-L1-high (HR: 0.41; 95% CI: 0.34-0.49) and PD-L1 low (HR: 0.63; 95% CI: 0.55-0.72; interaction-p = 0.00002) and PD-L1-high and PD-L1-negative (HR: 0.72; 95% CI: 0.65-0.80; interaction-p <0.00001). Similar benefits were observed regardless of gender, EGFR/ALK status and histological subtype. PD-L1 status is predictive of CIT benefit and may assist patient selection and design of future trials.

AB - We investigate if PD-L1 expression and other clinical characteristics predict chemoimmunotherapy (CIT) benefits versus chemotherapy in advanced non-small-cell lung cancer. We performed a meta-analysis of randomized controlled trials of CIT versus chemotherapy identified through electronic searches. In seven randomized controlled trials (n =4170), CIT prolonged progression-free survival over chemotherapy (hazard ratio [HR]: 0.62; 95% CI: 0.58-0.67; p <0.00001). The treatment benefits differed between PD-L1-high (HR: 0.41; 95% CI: 0.34-0.49) and PD-L1 low (HR: 0.63; 95% CI: 0.55-0.72; interaction-p = 0.00002) and PD-L1-high and PD-L1-negative (HR: 0.72; 95% CI: 0.65-0.80; interaction-p <0.00001). Similar benefits were observed regardless of gender, EGFR/ALK status and histological subtype. PD-L1 status is predictive of CIT benefit and may assist patient selection and design of future trials.

KW - chemoimmunotherapy

KW - meta-analysis

KW - non-small-cell lung cancer

KW - PD-L1 expression

KW - progression-free survival

KW - AMERICAN SOCIETY

KW - SQUAMOUS-CELL

KW - OPEN-LABEL

KW - NIVOLUMAB

KW - CHEMOTHERAPY

KW - DOCETAXEL

KW - IMMUNOHISTOCHEMISTRY

KW - PEMBROLIZUMAB

KW - MECHANISMS

KW - PHASE-1

U2 - 10.2217/fon-2019-0105

DO - 10.2217/fon-2019-0105

M3 - Review article

VL - 15

SP - 2371

EP - 2383

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 20

ER -